Integrating social and biomedical science in HIV vaccine research: Obstacles, opportunities and ways forward

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 1-3

  Newman, Peter A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

acceptability of healthcare; clinical trials; community engagement; HIV vaccines; social sciences

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHAVIOR; BIOMEDICINE; CLINICAL TRIAL (TOPIC); HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SOCIOLOGY;

AIDS VACCINES; BEHAVIOR; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; RESEARCH; SOCIAL SCIENCES;

EID: 83155164578     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.162     Document Type: Review

References (18)

1. Newman PA. Towards a science of community engagement. Lancet 367(9507), 302 (2006).
2. Fuchs JD, Sobieszczyk ME, Hammer SM, Buchbinder SP. Lessons drawn from recent HIV vaccine efficacy trials. J. Acquir. Immune Defic. Syndr. 55(Suppl. 2), S128-S131 (2010).
3. Lau CY, Stansbury JP, Gust DA, Kafaar Z. Social and behavioral science in HIV vaccine trials; a gap assessment of literature. Expert Rev. Vaccines 8(2), 179-190 (2009).
4. Singh JA, Mill EJ. The abandoned trials of pre-exposure prophylaxis for HIV: What went wrong? PLoS Med. 2(9), e234 (2005).
5. Newman PA, Yim S, Daley A et al. "Once bitten, twice shy": participant perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine 29, 451-458 (2011).
6. Newman PA, Logie C, James L et al. "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am. J. Pub. Health 101(9), 1749-1758 (2011).
7. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
8. Rerks-Ngarm S, Pitisutthithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
9. Gust DA, Wiegand RE, Para M, Chen RT, Bartholow BN. HIV testing outside of the study among men who have sex with men participating in an HIV vaccine efficacy trial. J. Acquir. Immu. Defic. Syndr. 52(2), 294-298 (2009).
10. Institute of Medicine. Calling the shots: immunization finance policies and practices. National Academies Press, Washington, DC, USA (2000).
11. Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 24(11), 1749-1756 (2010).
12. Woolf SH. The meaning of translational research and why it matters. JAMA 299(2), 211-213 (2008).
13. Streefland PH. Introduction of a HIV vaccine in developing countries: social and cultural dimensions. Vaccine 21, 1304-1309 (2003). (Pubitemid 36263171)
14. Newman PA, Seiden DS, Roberts KJ, Kakinami L, Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ. Behav. 36(2), 321-333 (2009).
15. Montgomery C, Pool R. Critically engaging: integrating the social and the biomedical in international microbicides research. J. Int. AIDS Soc. 14(Suppl. 2), S4 (2011).
16. Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach about dissemination? Vaccine 26(20), 2528-2536 (2008).
17. Lindegger G, Millford C, Slack C, Quayle M, Xaba X, Vards E. Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. J. Acquir. Immu. Defic. Syndr. 43(5), 560-566 (2006). (Pubitemid 44885623)
18. Swartz L, Kagee A. Community participation in AIDS vaccine trials: empowerment or science? Soc. Sci. Med. 63, 1143-1146 (2006). (Pubitemid 44037142)